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1. Introduction 
Gestational diabetes mellitus is commonly defined as hyperglycemia with onset or first 
recognition during pregnancy. However, this definition of gestational diabetes does not 
exclude pregnant women with undiagnosed pre-existing diabetes that now accounts around 
1% of diabetes mellitus cases in pregnancy. Prompt identification of pre-existing diabetes, if 
compared with women with gestational diabetes mellitus, is essential, for the reason that 
women with pre-existing diabetes are at risk of giving birth to infants with serious 
malformations, and adverse pregnancy outcomes are increased in this cluster, too. These 
include serious injury at birth, increased probability of cesarean delivery, and increased 
incidence of newborn admission in intensive care unit. 
The incidence of gestational diabetes is unfortunately increasing, it accounts for 90% of cases 
of diabetes mellitus in pregnancy, and it has strong association with adverse pregnancy 
outcomes. Risk factors connected to gestational diabetes mellitus include older age, family 
history and previous history of gestational diabetes mellitus, obesity, polycystic ovary 
syndrome and high blood pressure (American Diabetes Association, 2009; Hedderson and 
Ferrara, 2008). If untreated, it may lead to diverse complications, such as fetal 
hyperinsulinemia, increased weight at birth, higher rates of cesarian deliveries, shoulder 
dystocia, more neonatal hypoglycemia, and is associated with concomitant preeclampsia in 
pregnant women. Therefore, given that gestational diabetes may have long-term 
pathological consequences for both mother and the child, it is important that it is recognized 
and correctly managed. 
Treatment of gestational diabetes is aimed to maintain euglycemia and it involves regular 
glucose monitoring, dietary modification, life style changes, exercise, and, when necessary, 
pharmacotherapy. Insulin therapy is the first choice of treatment, although glyburide and 
metformin may be indicated, too. In women receiving pharmacotherapy scheduled 
monitoring of fetal well-being with antenatal tests should be pursued. 
2. Non-pharmacological treatment 
Self-monitoring of blood glucose is considered to be essential during pregnancy. This is 
supported, for example by the fact, that self-monitoring of blood glucose in women with 
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mild gestational diabetes positively correlates with reduced rate of fetal overgrowth and 
gestational weight gain (Hawkins, 2010). Moreover, taking into account that excessive 
gestational weight gain correlates with postpartum weight retention, regular monitoring of 
blood glucose during pregnancy might certainly have long-term benefits (Siega-Riz et al., 
2009). Common fasting, preprandial and postprandial glucose tests are all recommended in 
order to attain adequate glycemic targets and reduce overall rate of large-for-gestational-age 
infant births (Aschwald et al., 2009; Jovanovic, 2008; Riskin-Mashiah et al., 2009). The 
frequency and timing of home glucose monitoring for gaining and maintaining target 
glucose levels should be individualized. Generally, the monitoring of blood glucose level is 
performed in the fasting state, and 1–2 hours after meals, too. Taking into account the 
increased risk of nocturnal hypoglycemia that may be present during the course of 
pregnancy; in pregnant women receiving insulin night testing or even continuous glucose 
monitoring might be suggested (McLachlan et al., 2007). 
It is recommended that women diagnosed with gestational diabetes should have expert 
dietitian counseling to ensure that medical nutrition therapy supports euglycemia, adequate 
nutritional intake and controlled weight gain. Dietary recommendations should be 
individualized for each patient. Moderate carbohydrate restriction and proper distribution 
of daily meals should be emphasized. Namely, six meals per day are recommendable, 
including three major meals and three smaller ones - snacks. As a result, it has been shown 
that restriction of carbohydrates to 35–40% will decrease maternal glucose levels and 
improve maternal and fetal outcomes (Major et al., 1998). For pregnant women with body 
mass index >30 kg/m2, a 30–33% calorie restriction is expected to reduce hyperglycemia and 
plasma triglycerides (Moore, 2010). Moreover, fetal-based strategy to govern maternal 
glucose control may notably improve outcomes for the fetus given that increased fetal 
abdominal circumference on an ultrasound (conducted between 28-34 weeks) has been 
found to be connected to increased insulin in amniotic fluid, thus directly revealing poor 
maternal glycemic control. Assessing the fetal response to maternal gestational diabetes 
mellitus by ultrasound measurement of fetal abdominal circumference starting in the second 
and early third trimesters and repeated every 2– 4 weeks can provide useful information (in 
combination with maternal self-monitoring of blood glucose levels) to guide management 
decisions (Metzger et al., 2007). 
Individually adjusted physical activity should be promoted, especially in overweight or 
obese women who are often insulin resistant and at risk for preeclampsia. Thus, the amount 
of physical activity consisting of 20 minutes aerobic training three days weekly for six 
weeks, has been shown to result in lower fasting glucose levels, lower glucose responses to a 
glucose challenge, and a lower glycated hemoglobin - HbA1c (Jovanovic-Peterson et al., 
1989).  Avery et al. (1997) have also observed improved glucose levels in women who 
exercised 30 minutes 3-4 times per week. The delay in requirement of insulin was reported 
in another study involving resistance training three times per week (Brankston et al., 2004). 
Exercises may not be advisable if obstetrical contraindications exist, or in cases in which 
physical activity actually worsens glycemic control.   
3. Pharmacological treatment 
Insulin is the first-line pharmacological intervention for gestational diabetes and it should be 
initiated in women diagnosed with gestational diabetes or impaired glucose tolerance who 
did not achieve glycemic control within two weeks by the sole application of individualized 
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nutrition plan. During pregnancy, the main objective of insulin therapy will be to attain 
glucose levels similar to those before pregnancy. If indicated, at the beginning small doses of 
insulin are to be administered, and then insulin doses should be gradually increased. This 
should be accompanied by the appropriate administration intervals until target glucose 
levels are attained. Taking into account that insulin resistance rises during the whole 
pregnancy period, the insulin regimens must be continuously monitored, reviewed and 
modified. This is particularly significant during the third trimester of pregnancy when the 
required dosage of insulin usually increases. Hypoglycemia prevention measurements 
should be clearly explained to all pregnant women on insulin therapy. Sill, insulin therapy is 
considered to be effective and safe, and it is regarded as the gold standard of 
pharmacotherapy for gestational diabetes. It has been well determined that the use of 
insulin to achieve glycemic targets reduces fetal and maternal morbidities. In this way, daily 
glucose control and diet that were associated with insulin treatment and additional obstetric 
interventions have been confirmed to reduce the incidence of shoulder dystocia and 
macrosomia (Horvath et al., 2010).   
A diversity of protocols can be used, but multiple injections are considered to be the most 
effective. The majority insulin protocols include intermediate-acting insulins, such as 
isophane, and short-acting insulins, such as regular recombinant, as well the insulin 
analogues aspart and lispro. Although isophane is the intermediate-acting insulin of the first 
choice for women with gestational diabetes, evidences also support the use of short-acting 
insulin analogues in women who require pharmacological treatment of gestational diabetes. 
Moreover, the use of insulin analogs in pregnancy presents the potential benefits of more 
closely mimicking biological pancreatic insulin secretion compared to regular insulin 
(Klieger et al., 2008).  
Insulin lispro is insulin analog with fast absorption rate and a short duration of action that 
improves postprandial glucose levels and reduces hypoglycemic episodes when injected 
immediately prior to meals (Anderson et al., 1997). In the study conducted by Jovanovic et 
al., (1999) it was of interest to compare the immunologic response to insulin lispro with that 
to regular human insulin, thereby assuring its safety for use in women with gestational 
diabetes, and to verify that it is effective. Anti-insulin antibody levels were similar in the 
two groups. Insulin lispro was not detectable in the cord blood. During a meal test, areas 
under the curve for glucose, insulin, and C-peptide were significantly lower in the lispro 
group. Mean fasting and postprandial glucose concentrations and end point HbA1c were 
similar in the two groups but the lispro group demonstrated fewer hypoglycemic episodes. 
Accordingly, in women with gestational diabetes mellitus, the use of insulin lispro enabled 
the attainment of near-normal glucose levels at the one hour post-prandial time point and 
was associated with normal anthropometric characteristics; whereas use of regular insulin 
was not able to blunt the one hour peak post-prandial response to a near-normal extent and 
resulted in infants with a tendency toward the disproportionate growth (Mecacci et al., 
2003). Bhattacharyya et al. (2001) reported no increase in adverse outcome using lispro 
insulin in diabetic pregnancies, in either gestational or pre-gestational diabetes. Likewise, 
there was no difference in respect to congenital anomalies of gestational diabetic groups, 
which used either insulin lispro or regular human insulin (Aydin et al., 2008).  
In consideration to insulin aspart use, it has been demonstrated that effective postprandial 
glycemic control in women with gestational diabetes mellitus who required insulin was 
brought about by insulin aspart through higher insulin peak and lower demand on 
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endogenous insulin secretion (Pettitt et al., 2003). In particular, the peak insulin 
concentration was higher and the peak glucose and C-peptide concentrations were lower 
with both insulin preparations than with no exogenous insulin. Moreover, glucose areas 
under the curve above baseline were significantly lower with insulin aspart, but not with 
regular insulin, than with no insulin. In another randomized, parallel, open-label, 
controlled, multicenter and multinational study of type 1 diabetes pregnancy the fetal 
outcome using insulin aspart was comparable with human insulin, with a tendency toward 
fewer fetal losses and preterm deliveries (Hod at al., 2008). In another study, insulin aspart 
was more effective than regular human isulin in decreasing postprandial glucose 
concentrations (Pettitt et al., 2007). The authors of this investigation found out that duration 
of insulin aspart injection 5 min before a meal rather than 30 min prior to meals offered a 
more convenient therapy for subjects with gestational diabetes mellitus. Moreover, overall 
safety and effectiveness of insulin aspart were comparable to regular human insulin in 
pregnant women with gestational diabetes mellitus. 
Glyburide and metformin are oral antidiabetics that may be considered as second line 
agents in cases of gestational diabetes with poor glycemic control with insulin, or in women 
who refuse insulin. This is supported by the fact that when compared with insulin, 
administration of oral hypoglycemic agents was not associated with risk of neonatal 
hypoglycemia, caesarean section, or large-for-gestational-age babies births (Dhulkotia et al., 
2010). No significant differences were found in maternal fasting or postprandial glycemic 
control, too. It appears that glyburide may be preferred, as metformin use is more likely to 
need supplemental insulin for glycemic control and in addition metformin crosses the 
placenta with possible long-term effects. It has been estimated that fetal levels of metformin 
may reach approximately half of maternal levels (Vanky et al., 2005). 
The sulfonylurea glyburide is safe and effective at controlling glucose levels in majority of 
pregnant women with gestational diabetes mellitus. The study of Langer et al. (2005) was 
aimed to investigate the association between glyburide dose, degree of severity in 
gestational diabetes mellitus, level of glycemic control, and pregnancy outcome in insulin- 
and glyburide-treated patients. It has been reported that glyburide and insulin were equally 
efficient for treatment of gestational diabetes mellitus in all levels of disease severity. In 
earlier investigation it was also demonstrated that there were no significant differences 
between the glyburide and insulin groups in the percentage of infants who were large for 
gestational age, who had macrosomia, who had lung complications, who had 
hypoglycemia, who were admitted to a neonatal intensive care unit; or who had fetal 
anomalies (Langer et al., 2000). Glyburide is regarded as a pharmacologically active 
substance that minimally crosses placenta, as supported by different in vitro and in vivo 
investigations that demonstrated very low transplacental transport of glyburide to the fetal 
circulation. This is due to high plasma protein binding, short half-life, as well as its active 
transport from the fetus to the mother (Bertini et al., 2005; Koren 2001; Kraemer et al., 2006). 
In the study aimed to identify placental transporters potentially involved in limiting the 
transplacental transfer of glyburide to the fetus it was demonstrated that glyburide is 
preferentially transported by the breast cancer resistance protein pump and multidrug 
resistance-associated protein 3, that are highly expressed in placental tissues and limit the 
passage of therapeutic or toxic xenobiotics to the fetus (Gedeon et al., 2006).  Unfortunately, 
poor clinical response to glyburide has been reported in women with higher fasting and 
postprandial glucose values on their oral glucose tolerance test or in the group of diabetic 
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women on diet therapy. Other identified predictors of glyburide treatment failure were 
advanced maternal age, earlier diagnosis of gestational diabetes mellitus, higher gravidity 
or higher parity (Kahn et al., 2006). Otherwise, glyburide can be recommended for women 
in whom insulin cannot be used. In that way, it has been confirmed that this oral 
hypoglycemic can be used safely and effectively during the second and the third trimester of 
pregnancy without increasing maternal or fetal complications when compared with insulin 
(Langer et al., 2000). Glyburide has been shown to be safe in breastfeeding, too (Feig et al., 
2005). However, it has to be emphasized that in some investigations a glyburide-related 
increased risk of preeclampsia, macrosomia, neonatal hypoglycemia, admission to a 
neonatal intensive care unit; as well a need for phototherapy have been reported (Jacobson 
et al., 2005; Ramos et al., 2007). 
The second oral antidiabetic drug used in gestational diabetes mellitus, as a monotherapy or 
with supplemental insulin, is metformin, a biguanide. It lowers blood glucose levels by 
decreasing hepatic gluconeogenesis, increasing peripheral glucose disposal and reducing 
intestinal glucose absorption (Hundal & Inzucchi, 2003). In average, up to half the women 
using metformin may require supplemental insulin. It has been demonstrated that women 
requiring supplemental insulin had a higher body mass index and had higher baseline 
glucose levels (Rowan et al. 2008). If compared to insulin, metformin was not associated 
with increased perinatal complications except of higher incidence of perinatal mortality if 
administered during the third trimester (Hellmuth et al., 2000). Although it may appear that 
metformin is safe alternative to insulin therapy, it does cross the placenta (Vanky et al., 
2005) and scientific data are still not conclusive enough to recommend the standard use of 
metformin during pregnancy beyond the first trimester. Data that are more recent suggested 
that in women with gestational diabetes mellitus, not controlled with diet and exercise, who 
were then randomized to the metformin or the insulin arm, metformin has been shown to be 
an effective alternative to insulin in the treatment of gestational diabetes mellitus (Moore et 
al., 2007). This was substantiated by findings showing that difference in the rate of cesarean 
delivery was not statistically significant between the two groups, neither the neonatal 
statistics involving birth weight, Apgar score at 5 minutes, respiratory distress syndrome, 
hyperbilirubinemia, neonatal hypoglycemia or neonatal intensive care unit admission. 
Likewise, in investigation of Rowan et al. (2008) women with gestational diabetes mellitus at 
20 to 33 weeks of gestation were randomly assigned to open treatment with metformin 
(with supplemental insulin if required) or insulin. The primary outcome was a composite of 
neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute 
Apgar score less than 7, or prematurity. The rate of the primary composite outcome was 
comparable between the group assigned to metformin and the insulin group, suggesting 
that in women with gestational diabetes mellitus, metformin (alone or with supplemental 
insulin) was not associated with increased perinatal complications as compared with 
insulin. The retrospective data of Tertti et al. (2008) have been also indicative for the 
assumption that metformin was effective in controlling gestational diabetes and was not 
associated with a higher risk of maternal or neonatal complications compared with insulin. 
Namely, there were no differences between the metformin-treated group and the other two 
investigated groups (women treated with insulin and women with no pharmacological 
treatment) in terms of maternal outcomes (total weight gain during pregnancy or after the 
diagnosis of gestational diabetes mellitus, pre-pregnancy hypertension, pregnancy induced 
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hypertension, pre-eclampsia etc.). In this investigation, no differences between the 
metformin-treated group and the other two groups were observed in relation to mean birth 
weights, prevalence of macrosomia, or gestational weeks at delivery. Finally, there were no 
differences between the groups in relation to other neonatal outcomes (small for gestational 
age, Apgar scores, umbilical artery pH or base excess, etc.). This drug is contraindicated in 
the case of preeclampsia, intrauterine growth restriction or placental insufficiency. 
Moreover, given that metformin crosses placenta, it could increase insulin sensitivity in the 
fetus, thus probably affecting growth and fetal hepatic glucose production. 
4. Postpartum considerations 
After delivery, it is fundamental that women receive the appropriate postpartum 
counseling, testing, and follow-up. In a long-term view, most women with gestational 
diabetes do not require insulin therapy following delivery. Nevertheless, glucose levels 
should be regularly checked after discharge, since it has been confirmed that the progression 
of gestational diabetes mellitus to type 2 diabetes increased steeply within the first 5 years 
after delivery and appeared to plateau after 10 years (Kim et al., 2002). It has been 
determined that progressive beta-cell failure to compensate for the ongoing insulin 
resistance correlates with progression from gestational diabetes mellitus to type 2 diabetes. 
Insulin resistance that presents as a high serum insulin concentrations in association with 
blood glucose concentrations that are normal or high, results from defects in insulin 
responsiveness in muscle, fat and liver. Therefore, screening for diabetes at regular intervals 
should be of paramount importance. In addition, among women with a family history of 
type 2 diabetes, those with prior gestational diabetes mellitus were even more likely not 
only to have cardiovascular disease risk factors, including metabolic syndrome and type 2 
diabetes, but also to have experienced cardiovascular disease events, which occurred at a 
younger age (Carr et al., 2006). Moreover, the development of metabolic syndrome in 
children with increasing age is known to be related to maternal gestational diabetes 
mellitus, maternal glycemia in the third trimester, maternal obesity, neonatal macrosomia, 
and childhood obesity (Vohr  & Boney, 2008). Consequently, post partum evaluation and 
management of reversible cardiovascular risk factors such as smoking, obesity, 
hypertension, and hyperlipidemia should be undertaken (Cheung, 2009).  
It is confirmed that a good predictor of early postpartum development of diabetes is 
elevated fasting plasma glucose during pregnancy and, in women having positive tests to 
specific autoantibodies [anti-glutamic acid decarboxylase (anti-GAD); anti-protein tyrosine 
phosphatase ICA 512 (anti–IA-2)], higher incidence of diabetes by six months postpartum 
has been shown, too. In addition, it should be pointed out that some women with 
gestational diabetes mellitus, especially lean ones under 30 years of age who required 
insulin during pregnancy, could progress to type 1 diabetes. Therefore, women diagnosed 
with gestational diabetes should be screened for diabetes 6 to 12 weeks postpartum and 
should have subsequent screening for the development of diabetes or prediabetes 
(American Diabetes Association, 2009). An oral glucose tolerance test at three-year intervals 
has been also shown to be a beneficial approach for screening. 
All women with gestational diabetes should be encouraged on a healthy lifestyle and in 
order to prevent diabetes and cardiovascular complications education on lifestyle 
modification should start in pregnancy and continue postpartum. In that way, usual 
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recommendations to promote postpartum weight adjustments and decrease the incidence of 
type 2 diabetes include breastfeeding, exercising at a moderate intensity, and modifications 
of nutrition for specific weight-loss objectives (National Collaborating Centre for Women’s 
and Children’s Health, 2008). It has been determined that breastfeeding itself promotes 
weight loss for the mother, decreases possibility of maternal progression to type 2 diabetes, 
reduces insulin resistance in mothers and decreases likelihood of obesity in the child. 
Children born to mothers who had poor glycemic control should undergo regular 
evaluations of height, weight and blood glucose concentration, as well as monitoring for 
appropriate physical activity and diet to minimize the likelihood of obesity (Elchalal, 2004). 
5. Conclusion 
The incidence of gestational diabetes is increasing and this pathological condition has strong 
association with adverse pregnancy outcomes. If untreated, gestational diabetes may lead to 
diverse complications, such as fetal hyperinsulinemia, increased weight at birth, higher rates 
of cesarian deliveries, shoulder dystocia, neonatal hypoglycemia, and it is also associated 
with concomitant preeclampsia in pregnant women. Therefore, given that gestational 
diabetes may have long-term pathological consequences for both mother and the child, it is 
important that it is recognized and correctly managed. Moreover, preconceptional screening 
and medical informing of women with diabetes type 1 or 2 would be significant in order to 
reduce risk to the fetus and mother connected to gestational diabetes. Treatment of 
gestational diabetes is aimed to maintain euglycemia and it should involve regular glucose 
monitoring, dietary modification, life style changes, exercise, and, when necessary, 
pharmacotherapy. Insulin therapy is the first choice of treatment, although glyburide and 
metformin could be indicated, too. In a long-term view, in order to prevent development of 
diabetes later in life, as well as different cardiovascular complications, an adequate 
education on lifestyle modifications should start in pregnancy and continue postpartum. 
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